Mariane Fonck1, Jean-Thomas Perez2, Vittorio Catena2, Yves Becouarn1, Laurent Cany3, Eric Brudieux4, Laure Vayre5, Patrick Texereau6, Valérie Le Brun-Ly7, Véronique Verger8, Véronique Brouste9, Dominique Bechade1, Xavier Buy2, Jean Palussière10. 1. Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France. 2. Department of Interventional Radiology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France. 3. Department of Oncology, Clinique Francheville, 38 Boulevard de Vésone, 24000, Périgueux, France. 4. Department of Oncology, CH Pôle de Santé du Villeneuvois, Brignol Romas, 47305, Villeneuve-Sur-Lot, France. 5. Department of Oncology, CH Brive Bd Docteur Verlhac, 19100, Brive-La-Gaillarde, France. 6. Department of Oncology, Centre Hospitalier, Avenue Pierre de Coubertin BP 417, 40024, Mont-De-Marsan, France. 7. Department of Oncology, CHU Limoges, 2 Avenue Martin Luther King, 87042, Limoges, France. 8. Department of Oncology, CHI du pays de Cognac, 65 avenue d'Angoulême, 16112, Cognac, France. 9. Department of Clinical and Epidemiological Research, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France. 10. Department of Interventional Radiology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France. j.palussiere@bordeaux.unicancer.fr.
Abstract
BACKGROUND: Chemotherapy (ct) is the preferred treatment option in metastatic colorectal cancer (mCRC). The objective of the study was to determine the overall survival (OS), disease-free survival (DFS) and ct-free survival (CFS) of pulmonary thermal ablation (TA) and its place in the treatment of mCRC. PATIENTS AND METHODS: All consecutive patients treated (over 11 years) with percutaneous TA for lung metastasis of colorectal origin were reviewed. All sequences of treatments were considered. We determined the OS, DFS and CFS of pulmonary TA. RESULTS: Two hundred and nine patients underwent 323 TA procedures for 630 lung metastases. Majority of the metastases (71.5%) were unilateral with a median diameter of 10 mm (2-46). A single metastasis was treated in 95 patients (45.5%), and 2-8 in 114 patients (54.5%). One hundred and thirty-two patients (63.2%) had only a single procedure, 77 patients (36.8%) had 2-5 procedures. Following the first TA (n = 209), 125 patients (59.8%) resumed ct. Sixty-four out of the 126 patients presenting lung progression were treated again with TA. The median CFS was 12.2 months (95% CI: 10.3-17.7). Patients with no extra-pulmonary metastases showed a statistically better CFS than those who had extra-pulmonary metastases with a median of 20.9 and 9.2 months, respectively (p < 0.001). Median follow-up and OS were 50 and 67.6 months, respectively. CONCLUSION: This study demonstrates, for the first time, that TA enables a CFS of 12.2 months that extended to 20.9 months in patients who presented with lung-only metastases. TA is a viable option for a pause in the therapy of mCRCs.
BACKGROUND: Chemotherapy (ct) is the preferred treatment option in metastatic colorectal cancer (mCRC). The objective of the study was to determine the overall survival (OS), disease-free survival (DFS) and ct-free survival (CFS) of pulmonary thermal ablation (TA) and its place in the treatment of mCRC. PATIENTS AND METHODS: All consecutive patients treated (over 11 years) with percutaneous TA for lung metastasis of colorectal origin were reviewed. All sequences of treatments were considered. We determined the OS, DFS and CFS of pulmonary TA. RESULTS: Two hundred and nine patients underwent 323 TA procedures for 630 lung metastases. Majority of the metastases (71.5%) were unilateral with a median diameter of 10 mm (2-46). A single metastasis was treated in 95 patients (45.5%), and 2-8 in 114 patients (54.5%). One hundred and thirty-two patients (63.2%) had only a single procedure, 77 patients (36.8%) had 2-5 procedures. Following the first TA (n = 209), 125 patients (59.8%) resumed ct. Sixty-four out of the 126 patients presenting lung progression were treated again with TA. The median CFS was 12.2 months (95% CI: 10.3-17.7). Patients with no extra-pulmonary metastases showed a statistically better CFS than those who had extra-pulmonary metastases with a median of 20.9 and 9.2 months, respectively (p < 0.001). Median follow-up and OS were 50 and 67.6 months, respectively. CONCLUSION: This study demonstrates, for the first time, that TA enables a CFS of 12.2 months that extended to 20.9 months in patients who presented with lung-only metastases. TA is a viable option for a pause in the therapy of mCRCs.
Authors: Kaisa Lehtomäki; Hanna P Stedt; Emerik Osterlund; Timo Muhonen; Leena-Maija Soveri; Päivi Halonen; Tapio K Salminen; Juha Kononen; Raija Kallio; Annika Ålgars; Eetu Heervä; Annamarja Lamminmäki; Aki Uutela; Arno Nordin; Juho Lehto; Tiina Saarto; Harri Sintonen; Pirkko-Liisa Kellokumpu-Lehtinen; Raija Ristamäki; Bengt Glimelius; Helena Isoniemi; Pia Osterlund Journal: Cancers (Basel) Date: 2022-03-28 Impact factor: 6.639
Authors: Francesco De Cobelli; Marco Calandri; Angelo Della Corte; Roberta Sirovich; Carlo Gazzera; Paolo Della Vigna; Guido Bonomo; Gianluca Maria Varano; Daniele Maiettini; Giovanni Mauri; Nicola Camisassi; Stephanie Steidler; Francesca Ratti; Simone Gusmini; Monica Ronzoni; Luca Aldrighetti; Bruno C Odisio; Patrizia Racca; Paolo Fonio; Andrea Veltri; Franco Orsi Journal: Eur Radiol Date: 2022-01-29 Impact factor: 7.034
Authors: Charles Sutton; Yachao Zhang; DaeHee Kim; Hooman Yarmohammadi; Etay Ziv; Franz E Boas; Constantinos T Sofocleous; William D Tap; Sandra P D'Angelo; Joseph P Erinjeri Journal: Sarcoma Date: 2020-02-14